Table 1.
Clinicopathologic features according to epidermal growth factor receptor R521K polymorphism status in KRAS wild‐type colorectal carcinoma patients (n = 112)
| Characteristics | G/G (wild‐type) (%) | G/A or A/A (%) | P |
|---|---|---|---|
| All patients | 36 (100) | 76 (100) | |
| Age, years | |||
| <50 | 14 (38.9) | 26 (34.2) | 0.63 |
| ≥50 | 22 (61.1) | 50 (65.8) | |
| Gender | |||
| Male | 25 (69.4) | 55 (72.4) | 0.75 |
| Female | 11 (30.6) | 21 (27.6) | |
| Performance status | |||
| 0 | 26 (72.2) | 53 (69.7) | 0.79 |
| 1, 2 | 10 (27.8) | 23 (30.3) | |
| Primary tumor | |||
| Colon | 24 (62.1) | 57 (69.0) | 0.36 |
| Rectum | 12 (37.9) | 19 (31.0) | |
| VEGF expression | |||
| Higher (≥10% positive cells) | 24 (66.7) | 22 (28.9) | <0.01 |
| Lower (<10% positive cells) | 12 (33.3) | 54 (71.1) | |
| At least one tumor ≥6 cm | |||
| Present | 20 (55.6) | 24 (31.6) | 0.02 |
| Absent | 16 (44.4) | 52 (68.4) | |
| Histologic differentiation | |||
| Good/moderate | 23 (63.9) | 65 (85.5) | 0.01 |
| Poor | 13 (36.1) | 11 (14.5) | |
| Lymphovascular invasion | |||
| Present | 25 (69.4) | 30 (39.5) | <0.01 |
| Absent | 11 (30.6) | 46 (60.5) | |
| ERCC1 codon 118 genotype | |||
| C/C (wild‐type) | 17 (47.2) | 35 (46.1) | 0.91 |
| C/T or T/T | 19 (52.8) | 41 (53.9) | |
| XPD codon 751 status | |||
| Lys/Lys (wild‐type) | 31 (86.1) | 63 (82.9) | 0.67 |
| Lys/Gln | 5 (13.9) | 13 (17.1) | |
| TSER 28‐bp polymorphism | |||
| 2R/2R or 2R/3R | 12 (33.3) | 27 (35.5) | 0.82 |
| 3R/3R | 24 (66.7) | 49 (64.5) | |
bp, base pair; ERCC1, excision repair cross‐complementing group 1; TSER, 5′‐enhancer region of the thymidylate synthase gene; VEGF, vascular endothelial growth factor; XPD, xeroderma pigmentosum group D.